Stoke Therapeutics (NASDAQ:STOK) just reported results for the first quarter of 2024.
- Stoke Therapeutics reported earnings per share of -57 cents. This was above the analyst estimate for EPS of -61 cents.
- The company reported revenue of $4.22 million.
- This was 31.34% better than the analyst estimate for revenue of $3.21 million.